Cargando…
Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628498/ https://www.ncbi.nlm.nih.gov/pubmed/23606815 http://dx.doi.org/10.1155/2013/479805 |
_version_ | 1782266433289322496 |
---|---|
author | Murata, Satoru Mine, Takahiko Ueda, Tatsuo Nakazawa, Ken Onozawa, Shiro Yasui, Daisuke Kumita, Shin-ichiro |
author_facet | Murata, Satoru Mine, Takahiko Ueda, Tatsuo Nakazawa, Ken Onozawa, Shiro Yasui, Daisuke Kumita, Shin-ichiro |
author_sort | Murata, Satoru |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According to the BCLC staging system, curative therapies (resection, transplantation, and percutaneous ablation) can improve survival in HCC patients diagnosed at an early stage and offer potential long-term curative effects. Patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization (TACE), and those diagnosed at an advanced stage receive sorafenib, a multikinase inhibitor, or conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidates for systemic therapy. TACE is often recommended for advanced-stage HCC patients all over the world because these patients desire therapy that is more effective than systemic chemotherapy or conservative treatment. This paper aims to summarize both the published data and important ongoing studies for TACE and to discuss technical improvements in TACE for advanced-stage HCC. |
format | Online Article Text |
id | pubmed-3628498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36284982013-04-19 Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma Murata, Satoru Mine, Takahiko Ueda, Tatsuo Nakazawa, Ken Onozawa, Shiro Yasui, Daisuke Kumita, Shin-ichiro ScientificWorldJournal Review Article Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According to the BCLC staging system, curative therapies (resection, transplantation, and percutaneous ablation) can improve survival in HCC patients diagnosed at an early stage and offer potential long-term curative effects. Patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization (TACE), and those diagnosed at an advanced stage receive sorafenib, a multikinase inhibitor, or conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidates for systemic therapy. TACE is often recommended for advanced-stage HCC patients all over the world because these patients desire therapy that is more effective than systemic chemotherapy or conservative treatment. This paper aims to summarize both the published data and important ongoing studies for TACE and to discuss technical improvements in TACE for advanced-stage HCC. Hindawi Publishing Corporation 2013-03-27 /pmc/articles/PMC3628498/ /pubmed/23606815 http://dx.doi.org/10.1155/2013/479805 Text en Copyright © 2013 Satoru Murata et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Murata, Satoru Mine, Takahiko Ueda, Tatsuo Nakazawa, Ken Onozawa, Shiro Yasui, Daisuke Kumita, Shin-ichiro Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
title | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
title_full | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
title_fullStr | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
title_full_unstemmed | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
title_short | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
title_sort | transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628498/ https://www.ncbi.nlm.nih.gov/pubmed/23606815 http://dx.doi.org/10.1155/2013/479805 |
work_keys_str_mv | AT muratasatoru transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT minetakahiko transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT uedatatsuo transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT nakazawaken transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT onozawashiro transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT yasuidaisuke transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT kumitashinichiro transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma |